BCR and B-cell chronic lymphocytic leukemia: The observation that CLL cells sampled during the lymphocytosis phase or when progression on ibrutinib therapy remained responsive to TG02 (Fig. 7), together with the synergistic combination of TG02 and ibrutinib, suggested that TG02 could be combined with BCR antagonists in the clinic, or be used in CLL patients who are refractory to the BCR pathway-directed drugs.